Stephanie Phan

Quality System Engineer at Galvanize Therapeutics, Inc.

Stephanie Phan has a diverse work experience spanning multiple industries. Their most recent role is as a Quality System Engineer at Galvanize Therapeutics, Inc. where they started in June 2022. Before that, they worked as a Technical Project Manager at Nutek Bravo from November 2020 to June 2022. Stephanie also has experience as a Bioinformatician Intern at Aromyx Corporation from August 2019 to November 2020. Additionally, they worked as a Manufacturing Technician at Tecan in June and July 2019. Prior to that, Stephanie was a Student Assistant at Student Computer Services from August 2018 to July 2019. Stephanie also gained research experience as a Research Assistant at San Jose State University from June 2017 to May 2019, where they participated in a study on blood clot mechanical response. Lastly, Stephanie worked as a Robotics Instructor at UC Berkeley College of Engineering in the summer of 2018, where they taught students basic engineering skills.

Stephanie Phan pursued their education from 2015 to 2020 at San Jose State University, focusing on Biomedical/Medical Engineering. During their undergraduate years, they achieved the distinction of being a Dean's list scholar in 2017. Moving forward, Stephanie is currently enrolled in San Jose State University for their Master's degree in Biomathematics, Bioinformatics, and Computational Biology, expected to be completed in 2025.

Location

Milpitas, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Galvanize Therapeutics, Inc.

1 followers

Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.


Employees

51-200

Links